Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

How to Qualify Container Closure Systems for Intended Use, Part 1

Author(s):  Kim Amy A, Gehrmann Matthew R, McCaw James, McAndrew T Page

Issue:  Nov/Dec 2019 - Volume 23, Number 6
View All Articles in Issue

Page(s):  454-461

Note:  Electronic version includes errata or revisions.

How to Qualify Container Closure Systems for Intended Use, Part 1 Page 1
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 2
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 3
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 4
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 5
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 6
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 7
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 8

Download in electronic PDF format for $75

Abstract:  The U.S. Food and Drug Administration regulates outsourcing facilities with the same stringency they apply towards drug manufacturers. This means that outsourcing facilities, who must navigate the changing regulatory landscape to achieve and maintain 503B status, need to focus on qualifying container closure systems for their intended use. Container closure systems must be fit-for-purpose (i.e., suitable for in-use conditions relative to drug product stability over intended shelf-life and storage conditions). This article, the first of a two-part series, addresses the critical aspect of how to qualify systems for intended use regarding container closure integrity. The second part will address component selection.

Related Keywords: drug container closures, drug contamination, drug safety regulations, Current Good Manufacturing Practice, CGMP, Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act, 503B status, container closure integrity, fit for purpose, intended use, maximum allowable leak limit, sterile compounding, United States Pharmacopeia <1207> Packaging Integrity Evaluation--Sterile Products, USP, vial systems, stopper systems, seal systems, helium leak method, oxygen headspace method, residual seal force method, compression, microbial contaminants, drug contamination

Related Categories: LEGAL, PACKAGING, STERILE PREPARATIONS, QUALITY CONTROL, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
How to Qualify Container Closure Systems for Intended Use, Part 1
Kim Amy A
, Gehrmann Matthew R, McCaw James, McAndrew T Page
Nov/Dec 2019
Pg. 454-461

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems
Vaughn Stacey R
, Radwick Allison
Jan/Feb 2020
Pg. 14-19

Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
Jul/Aug 2021
Pg. 311-317

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
Sep/Oct 2014
Pg. 379-380

The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Parks Kenneth Chase
, Bernard Brian, Cogdill Christopher Blake
Sep/Oct 2015
Pg. 377-380

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

Quality Control Analytical Methods: A Summarized Discussion of Current Good Manufacturing Practice Regulations
Allen Loyd V Jr
May/Jun 2013
Pg. 210-219

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 1
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Jul/Aug 2021
Pg. 298-302

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Documentation: Records and Reports
Akers Michael J
Sep/Oct 2017
Pg. 373-380

Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
Mar/Apr 2022
Pg. 100-109

IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities
Miller David G
Mar/Apr 2014
Pg. 117-118

PreScription: Compounded Drugs Often Become Manufactured Drugs
Allen Loyd V Jr
Nov/Dec 2022
Pg. 444

Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective
Timko Robert J
, Crooker Philip EM
Mar/Apr 2014
Pg. 101-111

PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Williams LaVonn A
Nov/Dec 2011
Pg. 526-527

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Sep/Oct 2021
Pg. 389-395

Return to Top